Insider Selling: Globus Medical (NYSE:GMED) CFO Sells $363,353.40 in Stock

Globus Medical, Inc. (NYSE:GMED) CFO Kyle Kline sold 3,594 shares of the business’s stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $101.10, for a total value of $363,353.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Kyle Kline also recently made the following trade(s):

• On Monday, December 1st, Kyle Kline sold 18,542 shares of Globus Medical stock. The stock was sold at an average price of $90.00, for a total value of $1,668,780.00.

Globus Medical Stock Performance

Shares of GMED stock opened at $92.47 on Thursday. The stock has a 50 day simple moving average of $87.60 and a two-hundred day simple moving average of $68.64. The company has a market cap of $12.38 billion, a P/E ratio of 29.83, a PEG ratio of 1.51 and a beta of 1.06. Globus Medical, Inc. has a fifty-two week low of $51.79 and a fifty-two week high of $101.40.

Globus Medical (NYSE:GMED) last posted its quarterly earnings results on Thursday, November 6th. The medical device company reported $1.18 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.39. The firm had revenue of $769.05 million during the quarter, compared to the consensus estimate of $734.58 million. Globus Medical had a net margin of 15.30% and a return on equity of 11.52%. The business’s revenue was up 22.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.83 earnings per share. Globus Medical has set its FY 2025 guidance at 3.750-3.85 EPS. On average, research analysts predict that Globus Medical, Inc. will post 3.44 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on GMED shares. Stifel Nicolaus began coverage on Globus Medical in a research report on Tuesday, October 28th. They set a “hold” rating and a $64.00 target price on the stock. Piper Sandler restated an “overweight” rating and set a $115.00 price objective (up previously from $90.00) on shares of Globus Medical in a report on Thursday, January 8th. Zacks Research lowered shares of Globus Medical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 9th. Bank of America raised shares of Globus Medical from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $65.00 to $91.00 in a research report on Friday, November 7th. Finally, Citigroup restated a “market perform” rating on shares of Globus Medical in a report on Thursday, January 8th. Eight equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $97.78.

Institutional Trading of Globus Medical

Several institutional investors have recently made changes to their positions in GMED. Advisory Services Network LLC bought a new position in shares of Globus Medical during the third quarter valued at about $26,000. EverSource Wealth Advisors LLC increased its stake in Globus Medical by 74.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after buying an additional 197 shares during the last quarter. Advisors Asset Management Inc. bought a new position in shares of Globus Medical during the 2nd quarter worth approximately $28,000. First Horizon Corp purchased a new position in shares of Globus Medical in the 3rd quarter worth approximately $31,000. Finally, Parallel Advisors LLC boosted its stake in shares of Globus Medical by 45.1% in the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock worth $32,000 after buying an additional 173 shares during the last quarter. Institutional investors own 95.16% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.